Neogenomics (NEO) Equity Ratio (2010 - 2026)

Neogenomics has reported Equity Ratio for 17 years, with the latest figure at 0.62 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 10.96% year-over-year to 0.62; the trailing twelve-month figure through Mar 2026 stood at 0.62 (up 10.96% YoY), and the FY2025 full-year result was 0.62, up 11.68% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.62, roughly flat from 0.62 in the prior quarter.
• The five-year high for Equity Ratio was 0.62 in Q1 2026, with the low at 0.55 in Q4 2024.
• Historically, Equity Ratio has averaged 0.58 across 5 years, with a median of 0.57 in 2023.
• Annual changes were most pronounced in 2022 — Equity Ratio fell 3.85% — and 2025, when it grew 11.68%.
• Neogenomics' Equity Ratio stood at 0.57 in 2022, then slipped by 2.36% to 0.56 in 2023, then declined by 1.64% to 0.55 in 2024, then advanced by 11.68% to 0.62 in 2025, then grew by 0.05% to 0.62 in 2026.
• The last three Equity Ratio figures came in at 0.62 (Q1 2026), 0.62 (Q4 2025), and 0.61 (Q3 2025), per Business Quant data.